The application of phenotypic high-throughput screening techniques to cardiovascular research.
In traditional pure protein high-throughput drug screens, also called in vitro screens, individual compounds from a small molecule collection are tested to determine whether they inhibit the enzymatic activity or binding properties of a purified target protein. In contrast, phenotypic high-throughput drug screens, also called chemical genetic or in vivo screens, investigate the ability of individual compounds from a collection to inhibit a biological process or disease model in live cells or intact organisms. In this review, the role of phenotypic screening techniques to identify novel therapeutic agents for the treatment of cardiovascular disease will be discussed.
Etzion
Yoram
Y
Center for Cardiovascular Research, Washington University School of Medicine, MO 63110, USA.
Muslin
Anthony J
AJ
D000818:Animals; D002317:Cardiovascular Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D002319:Cardiovascular System / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D002478:Cells, Cultured; D020650:Combinatorial Chemistry Techniques; D003627:Data Interpretation, Statistical; D004195:Disease Models, Animal; D055808:Drug Discovery / Q000379:methods*; D057166:High-Throughput Screening Assays; D006801:Humans; D010641:Phenotype; D015398:Signal Transduction / Q000187:drug effects
D002317:Cardiovascular Agents